A Study of SI-F019 in Healthy Participants
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04851444
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center Ethics Committee Approval Letter, Shanghai, Shanghai, China
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 147
- Registration Number
- NCT04794972
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 159
- Registration Number
- NCT04606472
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT04606433
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04603287
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳West China Hospital，Sichuan University, Chengdu, Sichuan, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.
- Conditions
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 756
- Registration Number
- NCT03855826
- Locations
- 🇨🇳
Shenyang Military Region General Hospital, Shenyang, Liaoning, China
Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 2000
- Registration Number
- NCT03853369
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China